You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 15, April 16, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Revascularization
 •Cardiovascular System
 •Quality of Care
 •Patient Safety/ Medical Error
 •Surgery
 •Surgical Interventions
 •Cardiovascular/ Cardiothoracic Surgery
 •Randomized Controlled Trial
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Drug Therapy, Other
 •Cardiovascular Intervention
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

JAMA-EXPRESS
Efficacy and Safety of Pyridoxal 5'-Phosphate (MC-1) in High-Risk Patients Undergoing Coronary Artery Bypass Graft Surgery

The MEND-CABG II Randomized Clinical Trial

MEND-CABG II Investigators*

JAMA. 2008;299(15):1777-1787. Published online April 1, 2008 (doi:10.1001/jama.299.15.joc80027).

Context  Coronary artery bypass graft (CABG) surgery is frequently performed and effective; however, perioperative complications related to ischemia-reperfusion injury, including myocardial infarction (MI), remain common and result in significant morbidity and mortality. MC-1, a naturally occurring pyridoxine metabolite and purinergic receptor antagonist, prevents cellular calcium overload and may reduce ischemia-reperfusion injury. Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery.

Objective  To assess the efficacy and safety of MC-1 administered immediately before and for 30 days after surgery in patients undergoing CABG surgery.

Design, Setting, and Participants  The MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial, with 3023 intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass enrolled between October 2006 and September 2007 at 130 sites in Canada, the United States, and Germany.

Interventions  Patients received either MC-1, 250 mg/d (n = 1519), or matching placebo (n = 1504) immediately before and for 30 days after CABG surgery.

Main Outcome Measures  The primary efficacy outcome was cardiovascular death or nonfatal MI, defined as a creatine kinase (CK) MB fraction of at least 100 ng/mL or new Q waves through postoperative day 30.

Results  The primary efficacy outcome occurred in 140 of 1510 patients (9.3%) in the MC-1 group and 133 of 1486 patients (9.0%) in the placebo group (risk ratio, 1.04; 95% confidence interval, 0.83-1.30; P = .76). All-cause mortality was higher among patients assigned to MC-1 than placebo at 4 days (1.0% vs 0.3%; P = .03) but was similar at 30 days (1.9% vs 1.5%; P = .44). There was no difference in the 8- to 24-hour CK-MB area under the curve between the MC-1 and placebo groups (median, 270 [interquartile range, 175-492] vs 268 [interquartile range, 170-456] hours x ng/mL; P = .11).

Conclusion  In this population of intermediate- to high-risk patients undergoing CABG surgery, MC-1 did not reduce the composite of cardiovascular death or nonfatal MI.

Trial Registration  clinicaltrials.gov Identifier: NCT00402506


Authors/MEND-CABG II Writing Group: John H. Alexander, MD, MHS, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina; Robert W. Emery Jr, MD, Cardiovascular Surgery, St Joseph's Hospital, St Paul, Minnesota; Michel Carrier, MD, Montreal Heart Institute, Montreal, Quebec, Canada; Stephen J. Ellis, PhD, Duke Clinical Research Institute, Durham, North Carolina; Rajendra H. Mehta, MD, MHS, Duke Clinical Research Institute, Durham, North Carolina; Vic Hasselblad, PhD, Duke Clinical Research Institute, Durham, North Carolina; Philippe Menasche, MD, Hospital European George Pompidou, Paris, France; Ahmad Khalil, MD, PhD, Medicure International Inc, Winnipeg, Manitoba, Canada; Robert Cote, MD, Montreal Heart Institute, Montreal, Quebec, Canada; Elliott Bennett-Guerrero, MD, Duke University Medical Center, Durham, North Carolina; Michael J. Mack, MD, Cardiothoracic Surgery Associates of North Texas, Dallas; Gerhard Schuler, MD, University of Leipzig, Leipzig, Germany; Robert A. Harrington, MD, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina; Jean-Claude Tardif, MD, Montreal Heart Institute, Montreal, Quebec, Canada.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Clopidogrel Treatment and the MEND-CABG II Trial
Jaewon Oh, Namki Hong, and Seok-Min Kang
JAMA. 2008;300(9):1021.
EXTRACT | FULL TEXT  

Clopidogrel Treatment and the MEND-CABG II Trial—Reply
John H. Alexander, Stephen J. Ellis, and Jean-Claude Tardif
JAMA. 2008;300(9):1021-1022.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Industry-Sponsored Negative Trials and the Potential Pitfalls of Post Hoc Analysis
Curtis G. Tribble
Arch Surg. 2008;143(10):933-934.
EXTRACT | FULL TEXT  

Coronary Artery Bypass Grafting
Sharon Parmet, Cassio Lynm, and Richard M. Glass
JAMA. 2008;299(15):1856.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

'Conditioning' the heart during surgery
Venugopal et al.
Eur. J. Cardiothorac. Surg. 2009;35:977-987.
ABSTRACT | FULL TEXT  

Industry-Sponsored Negative Trials and the Potential Pitfalls of Post Hoc Analysis
Tribble
Arch Surg 2008;143:933-934.
FULL TEXT  

Clopidogrel Treatment and the MEND-CABG II Trial
Oh et al.
JAMA 2008;300:1021-1021.
FULL TEXT  

Highlights from the 57th Annual Scientific Session of the American College of Cardiology
Resnic and Desai
J. Thorac. Cardiovasc. Surg. 2008;136:244-247.
FULL TEXT  

All you need to read in the other general journals
BMJ 2008;336:914-915.
FULL TEXT  

MC-1 Fails to Improve Outcomes of Coronary Artery Bypass Grafting
Journal Watch Cardiology 2008;2008:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.